Salarius Pharmaceuticals, Inc.

NasdaqCM:SLRX Stock Report

Market Cap: US$2.1m

Salarius Pharmaceuticals Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

David Arthur

Chief executive officer

US$544.6k

Total compensation

CEO salary percentage91.8%
CEO tenure5.4yrs
CEO ownership0.4%
Management average tenureno data
Board average tenure5.4yrs

Recent management updates

Recent updates

Salarius pharmaceuticals announces 1-for-25 reverse stock split

Oct 14

Salarius adds 12% after updates on clinical programs and financials

Sep 13

Salarius Pharma adds two Mayo Clinic sites to phase 1/2 trial of Seclidemstat as treatment for cancers

Aug 22

Salarius Pharmaceuticals GAAP EPS of -$0.09 beats by $0.01

Aug 08

Salarius Pharmaceuticals and VolitionRx enter into R&D collaboration agreement

Aug 02

Salarius Pharma reports new seclidemstat results in Ewing sarcoma and other solid tumors at ASCO21

Jun 07

Salarius Pharmaceuticals (SLRX) Investor Presentation - Slideshow

May 27

Salarius Pharmaceuticals (NASDAQ:SLRX) Shareholders Have Enjoyed An Impressive 155% Share Price Gain

Feb 09
Salarius Pharmaceuticals (NASDAQ:SLRX) Shareholders Have Enjoyed An Impressive 155% Share Price Gain

Salarius Pharmaceuticals receives second installment of $1.7M in payments

Jan 13

Salarius Pharma raises $3.5M via warrant exercise

Dec 11

Salarius Pharmaceuticals EPS in-line, beats on revenue

Nov 11

CEO Compensation Analysis

How has David Arthur's remuneration changed compared to Salarius Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$5m

Jun 30 2024n/an/a

-US$6m

Mar 31 2024n/an/a

-US$9m

Dec 31 2023US$545kUS$500k

-US$13m

Sep 30 2023n/an/a

-US$18m

Jun 30 2023n/an/a

-US$30m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022US$941kUS$500k

-US$32m

Sep 30 2022n/an/a

-US$29m

Jun 30 2022n/an/a

-US$19m

Mar 31 2022n/an/a

-US$17m

Dec 31 2021US$677kUS$379k

-US$13m

Sep 30 2021n/an/a

-US$11m

Jun 30 2021n/an/a

-US$9m

Mar 31 2021n/an/a

-US$8m

Dec 31 2020US$1mUS$340k

-US$8m

Sep 30 2020n/an/a

-US$7m

Jun 30 2020n/an/a

-US$8m

Mar 31 2020n/an/a

-US$7m

Dec 31 2019US$518kUS$315k

-US$7m

Sep 30 2019n/an/a

-US$6m

Jun 30 2019n/an/a

-US$4m

Mar 31 2019n/an/a

-US$3m

Dec 31 2018US$275kUS$258k

-US$2m

Compensation vs Market: David's total compensation ($USD544.60K) is about average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.

CEO

David Arthur (61 yo)

5.4yrs

Tenure

US$544,600

Compensation

Mr. David J. Arthur, M.B.A., has been President at Salarius Pharmaceuticals, Inc since July 19, 2019 and Chief Executive Officer & Director at Salarius Pharmaceuticals, Inc. since July 2019. Mr. Arthur ser...

Board Members

NamePositionTenureCompensationOwnership
David Arthur
CEO, President & Director5.4yrsUS$544.60k0.43%
$ 9.2k
Jonathan Lieber
Independent Director4.5yrsUS$53.76k0.026%
$ 548.4
Paul Lammers
Lead Independent Director5.4yrsUS$76.76k0.015%
$ 320.4
Bruce McCreedy
Independent Director5.4yrsUS$45.26k0.012%
$ 268.2
Arnold Hanish
Independent Director5.4yrsUS$67.26k0.029%
$ 613.9
William McVicar
Chairman of the Board5.4yrsUS$82.26k0.025%
$ 531.9
Tess Burleson
Independent Director5.4yrsUS$64.76k0.024%
$ 506.6

5.4yrs

Average Tenure

65yo

Average Age

Experienced Board: SLRX's board of directors are considered experienced (5.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 07:00
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Salarius Pharmaceuticals, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aydin HuseynovBenchmark Company
Michael KingH.C. Wainwright & Co.